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Characterisation of tau in the human and
rodent enteric nervous system under
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Abstract
Tau is normally a highly soluble phosphoprotein found predominantly in neurons. Six different isoforms of tau are
expressed in the adult human CNS. Under pathological conditions, phosphorylated tau aggregates are a defining
feature of neurodegenerative disorders called tauopathies. Recent findings have suggested a potential role of the
gut-brain axis in CNS homeostasis, and therefore we set out to examine the isoform profile and phosphorylation
state of tau in the enteric nervous system (ENS) under physiological conditions and in tauopathies. Surgical
specimens of human colon from controls, Parkinson’s disease (PD) and progressive supranuclear palsy (PSP) patients
were analyzed by Western Blot and immunohistochemistry using a panel of anti-tau antibodies. We found that
adult human ENS primarily expresses two tau isoforms, localized in the cell bodies and neuronal processes. We did
not observe any difference in the enteric tau isoform profile and phosphorylation state between PSP, PD and
control subjects. The htau mouse model of tauopathy also expressed two main isoforms of human tau in the ENS,
and there were no apparent differences in ENS tau localization or phosphorylation between wild-type and htau
mice. Tau in both human and mouse ENS was found to be phosphorylated but poorly susceptible to
dephosphorylation with lambda phosphatase. To investigate ENS tau phosphorylation further, primary cultures from
rat enteric neurons, which express four isoforms of tau, were pharmacologically manipulated to show that ENS tau
phosphorylation state can be regulated, at least in vitro. Our study is the first to characterize tau in the rodent and
human ENS. As a whole, our findings provide a basis to unravel the functions of tau in the ENS and to further
investigate the possibility of pathological changes in enteric neuropathies and tauopathies.
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Introduction
The microtubule-associated protein tau is found predom-
inantly in neurons, where it exists as a highly soluble
protein that interacts with the cytoskeleton [25, 28]. Six
different isoforms of tau are expressed in the adult human
CNS via alternative splicing of the MAPT gene, which
comprises 16 exons. Regulated inclusion of exons 2 and 3
yields tau isoforms with 0, 1, or 2 N-terminal inserts (0 N,
1 N, 2 N, respectively), whereas exclusion or inclusion of
exon 10 leads to expression of tau isoforms with three
(3R) or four (4R) microtubule-binding repeats [28]. The
various splice combinations of tau are thus abbreviated
0N3R, 0N4R, 1N3R, 1N4R, 2N3R, 2N4R, encoding six
protein isoforms ranging from 352 to 441 amino acids
in length [25]. The function of tau is strongly affected
by its phosphorylation status, which influences its abil-
ity to interact with microtubules and various signaling
proteins [20, 57], as well as its localization and association
with membranes [56, 63]. Under pathological conditions,
aberrant assembly of highly phosphorylated tau into
insoluble aggregates is observed in a range of neurode-
generative disorders, collectively referred to as tauopathies.
Tauopathies encompass more than 20 clinicopathological
entities, including Alzheimer’s disease (AD), progressive
supranuclear palsy (PSP), Pick’s disease, all of which can be
biochemically subclassified according to the predominance
of tau isoforms found in the intracellular aggregates [43].
Tau aggregates found in tauopathies generally contain tau
in an elevated state of phosphorylation [7, 29, 34] that is
often aberrantly cleaved [31, 51]. Highly phosphorylated
forms of tau are also found in other neurodegenerative
diseases, including Parkinson’s disease (PD), where it often
colocalises with abnormal alpha-synuclein [39, 66].
The enteric nervous system (ENS) is an integrated neur-
onal network distributed from the lower esophagus to the
rectum. Compared to other components of the peripheral
nervous system, the ENS shows some unique features that
closely resemble the CNS and is sometimes referred to as
‘the brain-in-the-gut’ or the ‘second brain’. This close
homology between the CNS and ENS suggests that a dis-
ease process affecting the CNS could also involve its en-
teric counterpart, as has already been described in variant
Creutzfeldt-Jakob disease [33, 41] and PD [6, 21, 65].
Whether such a scenario can be extended to other neuro-
degenerative disorders such as tauopathies remains to be
demonstrated, and this was one focus of the current study.
A few studies have shown that tau is expressed in rodent
[30] and human [8, 17, 61] gastrointestinal (GI) tract, but
no data are available about the distribution and phos-
phorylation pattern of tau isoforms in the ENS. Here,
we examined the expression levels of tau isoforms, their
phosphorylation profile and truncation in sigmoid colon
biopsy specimens from PSP patients and compared them
to samples from PD patients and controls. We examined
the same tau characteristics in a mouse model of tauopa-
thy in comparison to wild-type mice. Our results show the
expression of two main human tau isoforms in the ENS.
ENS tau is phosphorylated but is remarkably resistant to
dephosphorylation with lambda phosphatase. We then
examined the isoform profile and phosphorylation state of
tau under physiological conditions in rat primary enteric
neuron cultures, which showed that ENS tau phosphoryl-
ation can be modified, at least in vitro. These data provide
the first detailed characterization of ENS tau in humans
and rodents in health and tauopathies. Further investiga-
tion of tau modifications in the ENS in disease may
provide valuable information about tau modifications that
promote or prevent tau abnormalities spreading between
the gut and brain in neurodegenerative diseases.
Material and methods
Human tissues
Samples of frozen temporal cortex from one post-mortem
human brain devoid of neurodegeneration were ob-
tained from the Neuropathology Department of Angers
(Dr Franck Letournel) to serve as a control for the
following experiments. Specimens of human colon were
obtained from three neurologically unimpaired subjects
who underwent colon resection for colorectal cancer. For
all three tissues specimens, sampling was performed in
macroscopically normal segments of uninvolved resection
margins. Colonic sections were separated into muscle and
submucosal/mucosal layer [36], which contain the my-
enteric and submucosal plexus respectively. Two out of
three samples were frozen and kept at − 80 °C until fur-
ther analysis by Western blot. The remaining sample was
analyzed by immunohistochemistry.
Routine sigmoid colon biopsies were obtained during
sigmoidoscopy/colonoscopy from 24 subjects, 10 with PD,
5 with PSP and 9 controls. All patients were recruited
from the movement disorder clinic at Nantes University
Hospital, France. Diagnosis of PD was made according to
criteria provided by the United Kingdom Parkinson’s
Disease Survey Brain Bank. PSP patients fulfilled the diag-
nostic criteria for possible or probable PSP. Control sub-
jects were healthy subjects who had a routine colonoscopy
performed for colorectal cancer screening. All controls
subjects underwent a detailed neurological examination to
rule out PD symptoms and cognitive deficiency. Except
for control subjects 183 and 208 (Table 1) who had 6
biopsies, 4 biopsies per patient were taken during the
endoscopic procedure. Biopsies were stored at − 80 °C
until required.
The sampling of human brain and colon was approved
by the Fédération des biothèques of the University Hospital
of Nantes, according to the guidelines of the French Ethics
Committee for Research on Humans and registered under
the no. DC-2008-402. Regarding sigmoid biopsies sampling,
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the study protocol was approved by the local Committee
on Ethics and Human Research (Comité de Protection des
Personnes Ouest VI), and registered on ClinicalTrials.gov
(EnteroLark and ColoBioParker, identifier NCT01618383
and NCT01353183, respectively). Written informed con-
sent was obtained from each patient and from each normal
volunteer.
Mouse tissues
Htau mice (B6.Cg-Mapttm1(EGFP)KltTg(MAPT)8cPdav/J)
were originally purchased from the Jackson laboratory
(Bar Harbor, ME, USA) and maintained at King’s College
London. Wild-type and tau knockout offspring of an
identical background strain (C57Bl/6 J) were obtained
via breeding. All housing and experimental procedures
were carried out in compliance with the local ethical re-
view panel of King’s College London under a UK Home
Office project license held in accordance with the Animals
(Scientific Procedures) Act 1986 and the European Direct-
ive 2010/63/EU. Two-month old male and female mice
were used in this study. Animals were housed at 19–22 °C,
humidity 55%, 12 h:12 h light: dark cycle with lights on at
07:30. Animals were culled using Schedule 1 methods,
brains removed and snap-frozen on dry-ice. Sections of
colon tissue were removed, with tissue from the distal por-
tion of each part being cleaned and snap-frozen on dry-ice,
prior to storage at − 80 °C for RNA extraction or biochem-
ical analysis. The proximal portion from each part of colon
along with the duodenum, jejunum and ileum were dis-
sected with fine forceps to reveal the myenteric plexus as
described previously [62].
Rat tissues
Sciatic nerve sections were taken from two pregnant
Sprague-Dawley rats (used for the generation of primary
culture of rat ENS, see below) to serve as a positive
control for big tau experiments [60].
Primary cultures of rat ENS
Primary culture of rat ENS were generated using preg-
nant Sprague–Dawley rats (Janvier Laboratories SA, Le
Genest-St-Isle, France) as previously described [11]. All
housing and experimental procedures were carried out in
compliance with the local ethical review panel of INSERM
(agreement E. 44,011; INSERM, Nantes, France). Pregnant
rats were killed by an overdose of CO2 followed by sever-
ing the carotid arteries. The small intestines of rat
embryos were removed, diced in Hank’s Buffered Salt
Solution (Sigma, Saint-Quentin Fallavier, France) and
collected in 5 mL of Dulbecco’s modified Eagle’s medium
(DMEM)-F12 (Gibco®, Life Technologies, Villebon sur
Yvette, France) (1:1) for digestion at 37 °C for 15 min in
0.1% (v/v) trypsin (Sigma). The trypsin reaction was
stopped by adding medium containing 10% fetal calf serum
and then treatment with DNase I 0.01% (v/v) (Sigma) for
10 min at 37 °C. After triturating with a 10 mL pipette, cells
were centrifuged at 750 rpm for 10 min. Cells were counted
and then seeded at a density of 2.4 × 105 cells/cm2 on
24-well plates previously coated with a solution of 0.5%
(v/v) gelatin in sterile phosphate buffered saline. After
24 h, the medium was replaced with a serum-free medium
DMEM-F12 (1:1) containing 1% (v/v) of N-2 supplement
(Life Technologies). Cultures were maintained for 14 days.
Treatment of rat ENS primary cultures with serine/
threonine phosphatases inhibitors
After 14 days in vitro (DIV), cells were treated with a
cocktail of three phosphatase inhibitors including 1 μM
okadaic acid, 1 μM ciclosporine A and 6.75 μM sangui-
narine (Sigma) for broad-spectrum inhibition of serine/
threonine phosphatases, or with vehicle (DMSO, Sigma)
for one hour.
Table 1 Demographics and characteristics of controls subjects
and patients
Patient # Age/sex Diagnosis DD
183 49/F Control –
188 67/F Control –
189 63/F Control –
190 45/M Control –
191 19/F Control –
208 76/M Control –
210 63/F Control –
214 69/F Control –
227 56/F Control –
162 56/F PD 12
166 64/F PD 11
167 67/M PD 10
168 55/F PD 4
171 71/M PD 3
173 67/M PD 11
175 70/M PD 12
177 70/F PD 8
178 53/F PD 1
179 52/F PD 4
170 63/F PSP 4
176 72/M PSP 4
185 72/F PSP 11
187 75/M PSP 5
228 76/F PSP 1
Patient ID, age, sex, diagnosis of PD or PSP (including probable PSP) are
shown in addition to disease duration (DD) in years
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Dephosphorylation of tissues and cell lysates
For dephosphorylation experiments, cells or tissues were
homogenised in a buffer containing 100 mM NaCl and
50 mM Tris-Cl at pH 7.4 with 1% (v/v) IGEPAL® CA-630
and a protease inhibitors cocktail without EDTA (Roche,
Neuilly sur Seine, France) using either a “Precellys 24”
(Bertin technologies, St Quentin-en-Yvelines, France) or a
Tissue Master 125 (Omni International, Kennesaw, GA,
USA) tissue homogenizer and followed by sonication with
“vibracell 75 186” device (Sonics, Newton CT, USA).
Homogenates were centrifuged at 16,300 g for 20 min at
4 °C with an Eppendorf 5415R centrifuge (Eppendorf,
Hamburg, Germany), sonicated for 10 s and protein
amounts normalized following a BCA protein assay
(ThermoFisher, Waltham, MA, USA). Samples were
diluted to 1.0 mg/mL protein using homogenisation buffer
and incubated with 20 U/μL lambda phosphatase in
MnCl2 and enzyme buffer as supplied with the lambda
protein phosphatase kit (New England Biolabs, Ipswich,
MA, USA) for 3 h at 30 °C. The reaction was stopped by
the addition of sample buffer (National Diagnostics, Hull,
UK or Life Technologies, Courtaboeuf, France) and heat-
ing to 95 °C for 5 min. Control samples were treated
identically without the addition of lambda phosphatase.
SDS-PAGE and western blot
For dephosphorylation experiments, cells or tissues were
processed as described above. For experiments that did
not require dephosphorylation, cells or tissues were
lysed in RIPA lysis buffer (Merck Millipore, Fontenay
sous Bois, France). Western blots were performed as we
previously described [10] using NuPAGE™ 10% Bis-Tris
Protein Gels (Life Technologies, Courtaboeuf, France).
The primary anti-tau antibodies used are listed in Table 2.
Phospho-ERK (Cell signaling, Ozyme, France 1:2000
dilution) and PGP 9.5 antibodies (Abcam, France, 1:1000
dilution) were used for the evaluation of phosphatase
treatment and as loading control, respectively.
Immunohistochemistry
For mouse GI tract tissues, following the excision of
myenteric plexus from mouse colon, tissue segments
were incubated in combined blocking (50 mM tris-buffered
saline [TBS] pH 7.4 containing 5% bovine serum albumen
[BSA] and 0.05% tween-20) and permeabilisation (50 mM
TBS pH 7.4, 0.1% triton X-100) solutions overnight at 4 °C.
Primary antibodies (Table 2) in blocking solution were
incubated with gut tissues overnight at 4 °C. Following wash-
ing in 50 mM TBS the appropriate fluorescently-tagged sec-
ondary antibody was added for 3 h at ambient temperature,
the antibodies removed by washing and Hoechst 33258
added for 3 min. Images were acquired using a CTR5000
digital camera (Leica Microsystems, Cambridge, UK) at-
tached to a Leica DM5000B fluorescence microscope with
Leica AIF lite software.
For human tissues, fixed human tissues were embed-
ded in paraffin using an embedding station (LEICA
EG1150C) and sections (3 μm) were cut using a micro-
tome (LEICA RM2255). The sections were deparaffi-
nised by bathing twice in xylene (for 5 min each) and
taken through graded concentrations of ethanol (100,
95, 70, 70%, respectively for 3 min each). After a rinse in
distilled water, slides were washed in PBS and antigen
retrieval was performed using a sodium citrate solution
(2.94 g Sodium Citrate Tribase; 1 L ultrapure water;
500 μL Tween 20; pH 6) at 95 °C for 20 min. Slides were
incubated in NH4Cl (100 mM) for 15 min before incuba-
tion in PBS-0.5% triton X-100 for 1 h and blocking for
Table 2 Tau antibodies used in this study
Name Specificity Epitope (a.a) Source and dilution
A0024 Tau All tau isoforms 243–441 (2N4R) Dako, rp (WB 1:1000; IHC 1:500)
TAU-5 All tau isoforms 210–241 (2N4R) ThermoFisher, mm (WB 1:1000)
Tau-1 All tau isoforms 189–207 (2N4R) Merck, mm, clone PC1C6 (WB 1:2000)
TP70 All tau isoforms 428–441 (2N4R) IOP, KCL, rp (WB 1:500)
Anti tau RD3 3R tau Isoforms 267–282 (2N3R) Merck, mm, clone 8E6 (WB 1:1000; IHC 1:500)
Anti tau RD4 4R tau isoforms 275–291 (2N4R) Merck, mm, clone 1E1/A6 (WB 1:1000)
Anti 4R-tau 4R tau isoforms NS Cosmo bio co., rp (WB 1:2000; IHC 1:1000)
Anti 0 N-tau 0 N Tau isoforms 39–50 (0N3R) BioLegend, mm (WB 1:500)
AT8 Tau ℗ S202/T205 Tau ℗ S202/T205 Innogenetics, mm (WB 1:1000)
PHF-1 Tau ℗ S396/S404 Tau ℗ S396/S404 Gift from Peter Davies, mm (WB 1:500)
PHF13 Tau ℗ S396 Tau ℗ S396 Cell Signaling, mm (WB 1:1000)
CP13 Tau ℗ S202 Tau ℗ S202 Gift from Peter Davies, mm (IHC 1:200)
The name, specificity, epitope, source and dilution of the antibodies used in this study are shown.
Abbreviations: a.a. amino-acids, IHC immunohistochemistry, IOP, KCL Institute of Psychiatry, King’s college London, mm mouse monoclonal, NS not specified, rp
rabbit polyclonal, WB western blot
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2 h in 10% horse serum in PBS-0.5% triton X-100. Pri-
mary antibodies (Table 2) were incubated overnight at
4 °C, and following washing, secondary antibodies were
added for 2 h at room temperature. Images were ac-
quired with an Olympus IX 50 fluorescence microscope
coupled to a digital camera (model DP71, Olympus).
RNA extraction and RT-PCR
Frozen proximal colon and cortex from htau, wild-type
and tau knockout mice was homogenised in approxi-
mately 100 mg/mL Quiazol® supplied with the Quiagen
RNA LipidEasy kit (Qiagen, Hilden, Germany), and
RNA was extracted following the manufacturer’s proto-
col. The RNA obtained was eluted in ultrapure H2O and
its concentration and purity determined using a Nano-
Drop spectrophotometer (Thermo Scientific, Waltham,
MA, USA). Samples were diluted to 1 μg RNA/15 μL
RNAse-free H2O, heat-shocked for 3 min at 72 °C to
break down double-stranded structures and returned
immediately to ice. One μg RNA per sample was reverse
transcribed using a Superscript III reverse transcriptase
assay kit (Life Technologies, Paisley, UK) according to
the manufacturer’s instructions. The resulting cDNA
was stored at − 20 °C until use. To examine the alternate
splicing of the microtubule binding domain repeat
region encoded by exon 10, primers were used that spe-
cifically recognize mouse or human exons 9 and 11 as
described by Duff et al. [16]. Primer sequences were: mouse
exon 9F 5’-CCCCCTAAGTCACCATCAGCTAGT, mouse
exon 11R 5’-CACTTTGCTCAGGTCCACCGGC, human
exon 9F 5’-CTCCAAAATCAGGGGATCGC, human exon
11R 5’-CCTTGCTCAGGTCAACTGGT. Splicing around
the N terminal insert domain encoded by exons 2 and 3
was detected using primers that recognize exons 1 and 5.
Primer sequences used were: mouse exon 1F 5’-TCCG
CTGTCCTCTTCTGTC, mouse exon 5R 5′- TTCTCG
TCATTTCCTGTCC, human exon 1F 5′- TGAACCA
GGATGGCTGAGC, human exon 5R 5’-TTGTCATCG
CTTCCAGTCC. Annealing temperatures were 64 °C (all
MAPT primers), 62 °C (M1F/M5R) and 68 °C (M9F/
M11R). 35 reaction cycles were used for all. Mouse and
human-specific RT-PCR products were analysed by agar-
ose gel electrophoresis. Products corresponding to exon
10+ tau mRNA (4R) are 390 base pairs (bp), while prod-
ucts corresponding to exon 10- mRNA (3R) are 297 bp.
RT-PCR products containing tau mRNA with exons 2 and
3 (2 N) are 428 bp, 2 + 3- mRNA products (1 N) are
341 bp, and 2–3- mRNA products (0 N) are 253 bp.
Statistics
All data shown are mean ± SEM. Statistical analyses was
conducted using GraphPad software version 5.00 (San
Diego California, USA). For comparisons of means between
groups, Kruskal-Wallis tests were performed. Differences
were deemed statistically significant when p < 0.05.
Results
The expression pattern of tau isoforms is different in
adult human brain and gut
In adult human brain, the six tau isoforms are phosphor-
ylated resulting in reduced electrophoretic mobility on
SDS-PAGE compared to recombinant tau [25]. In order
to identify the tau isoforms expressed in the human
ENS, colonic samples from healthy subjects treated or
not with lambda phosphatase [35] were analyzed by
western blot using the A0024 tau antibody that recog-
nizes all six tau isoforms. ENS samples were compared
to dephosphorylated and non-dephosphorylated brain
samples as well as to a recombinant tau ladder. The
banding pattern was markedly different between brain
and colonic samples (Fig. 1a). The A0024 Tau antibody
detected one major band migrating at 53–54 kDa in
both the submucosal and muscle layers (which contain
the submucosal and myenteric plexus, respectively and
therefore are referred to as SMP and MP) (Fig. 1a). This
band migrated only slightly faster after dephosphoryla-
tion of SMP and MP samples despite the efficiency of
the dephosphorylation treatment being validated by
phospho-ERK immunoblot, Fig. 1a). The major band
detected in ENS samples comigrated with 0N4R-1N3R
detected in human brain samples and the recombinant
tau ladder (red line in Fig. 1a) and was also observed
when a pan-tau (TAU-5) antibody was used (Fig. 1b). In
addition, a fainter band around 57–58 kDa in SMP and
a strong immunoreactive band at 62 kDa (white arrow)
in both SMP and MP were also observed when the
A0024 tau antibody was used (Fig. 1a). These two bands
are most likely non-specific as they were not observed
with TAU-5 (Fig. 1b) or with other specific antibodies
subsequently used in this study (Figs. 1b, c and 2).
To further refine this analysis, we used 3 commercially
available isoform-specific tau antibodies. Two of these
antibodies directed against 3R and 0 N-tau have been
shown to be highly specific in a recent comprehensive
study that tested the specificity of tau antibodies using
immunoblotting [19]. In addition, we used a 4R-tau anti-
body that only detects 4R tau isoforms in human brain ly-
sates and in tau ladder (Additional file 1: Figure S1). All of
these antibodies detected a single 53–54 kDa-band that
comigrates with the major band detected by TAU-5 and
with 0N4R-1N3R in the recombinant tau ladder (Fig. 1b).
Until recently, analysis of the ENS in humans was
mainly performed using full thickness specimens of the
gut obtained during surgery or autopsy. However, several
recent studies have shown that the ENS is accessible and
analyzable through routine GI biopsies, which can be
processed to measure quantitative differences in neuronal
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and/or glial markers [5, 23, 44]. We therefore analyzed the
expression levels of tau in routine sigmoid biopsies from 2
control subjects (#183 and 208, Table 1) with the pan-tau
antibody TAU-5 and with the 3R and 4R isoform-specific
antibodies. The immunoblotting pattern observed with
these 3 antibodies in biopsies was similar to those
observed in colonic SMP and MP samples (Fig. 1c).
“Big” or peripheral tau is a tau isoform specifically
expressed in the peripheral nervous system, including tri-
geminal, dorsal root and sympathetic ganglia as well as
Fig. 1 Tau isoforms and phosphorylation in adult human ENS. a Human brain and colon tissue lysates (submucosal and muscle layers, which
contains the submucosal (SMP) and myenteric plexus (MP), respectively) were subjected to immunoblot analysis using the pan-Tau antibody
A0024. Lysates were treated (+) or not (−) with lambda phosphatase before immunoblotting. The effectiveness of dephosphorylation was
confirmed by phospho-ERK immunoblot (P-ERK immunoblot). Tau antibody A0024 detected all six tau isoforms in the recombinant human tau
ladder and brain samples (the 2N4R was only visible on long exposure immunoblots, black arrow). The non-specific band detected by Tau
antibody A0024 in the ENS is marked by a white arrow. An antibody against protein gene product (PGP) 9.5 was used as a loading control.
b Colon tissue lysates (SMP and MP) were subjected to immunoblot analysis using antibodies specific to 0 N, 3R, 4R tau, the pan-tau TAU-5
antibody, and the phospho-specific tau antibodies AT8 (phos-Ser202/Thr205) and PHF13 (phos-Ser396). c Sigmoid colon biopsies lysates from 2
control subjects (#183 and 208, Table 2) were subjected to immunoblot analysis using the TAU-5 antibody, antibodies specific to the 3R and 4R
tau isoforms and the phospho-specific tau antibodies AT8 and PHF-1. In all experiments, the banding pattern was compared to that of tau ladder
which contains all six recombinant tau isoforms. The red line shows the comigration of the observed bands with 1 N3/0N4R. The results shown
in (a), (b) and (c) are representative of 3, 2 and 5 independent experiments, respectively
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sciatic nerve. It differs from the 2N4R tau isoform by a 254
amino-acid insert located in the amino-terminal half and
migrates at 110 kDa on SDS/PAGE [27]. To determine
whether big tau is expressed in the ENS, human colon
tissue lysates were analyzed by Western blot using Tau
A0024 antibody. Rat sciatic nerve lysates were used as
positive controls [60]. Tau A0024 detected the expected
low molecular weight tau isoforms between 45 and
60 kDa in human colon and rat sciatic nerve, however a
110 kDa migrating band was only observed with rat sciatic
nerve lysates (Fig. 2).
When taken together, these results show that 1N3R and
0N4R are the two main tau isoforms that are expressed in
human adult colon and these two isoforms can be detected
in routine GI biopsies. In addition, our work indicates that
big tau is not expressed in the adult human ENS.
Tau isoforms are differentially expressed in the gut and
brain of tauopathy mice
To determine if tau is also differentially expressed in the
ENS and CNS of mice, we used the transgenic htau mouse
model which expresses exclusively the six wild-type hu-
man isoforms of tau under the control of the MAPT
promoter [3]. The enteric expression profile of tau iso-
forms in these transgenic mice was compared to that
observed in wild-type mice. Tau knockout mice were
examined as an additional control. To this end, RNA from
2-month-old, wild-type, tau knockout and htau mouse
proximal colon was reverse transcribed to cDNA and
amplified with PCR. Brain tissue from the same mice was
used for comparison. Primers were designed, based on
those previously described by Duff et al. [16], to detect
splicing of human tau exons 2 and 3. This allowed amplifi-
cation of products corresponding to 0 N, 1 N and 2 N
human tau that were detected in htau, but not wild-type
or tau knockout, brain and proximal colon (Fig. 3). Tran-
scripts of 3R and 4R MAPT were also observed in htau brain
and proximal colon when inclusion of exon 10 was assessed
using primers specific to human tau exons 9 and 11 (Fig. 3).
Thus, 0 N, 1 N, 2 N, 3R and 4R human tau transcripts are
expressed in htau proximal colon.
Primers against mouse tau were also used to allow
detection of 0 N, 1 N and 2 N transcripts in wild-type
mouse brain and proximal colon (Fig. 3a). A weak non--
specific PCR product corresponding to the predicted size
of 0 N tau was also amplified in htau and tau knockout
samples with these primers. In addition, 4R, but not 3R
Mapt was detected in WT mouse brain, and a weak signal
was also apparent in proximal colon (Fig. 3a). These tran-
scripts were not amplified in htau or tau knockout tissues.
Thus, wild-type mice express 0 N, 1 N, 2 N and mainly 4R
tau in gut and brain.
The detection of multiple products in a single lane,
each corresponding to a different tau isoform, allows
each product to act as an internal control for the other
transcripts. This allowed us to make comparisons between
the relative abundance of tau isoforms in different tissues.
Htau brain showed 0 N > 1 N > 2 N relative abundance of
tau isoforms, in keeping with previous observations in
adult mice [59]. Htau mouse brain also showed greater ex-
clusion of tau exon 10 (3R > 4R), as previously reported
[3] and in contrast to adult wild-type mice where mainly
4R tau is expressed (Fig. 3; [59]). Thus, htau brain mirrors
human brain in that both 3R and 4R tau are expressed,
Fig. 2 Big tau is not detected in adult human ENS. Human brain and colon tissue lysates (SMP and MP) were subjected to immunoblot analysis
using the pan-Tau antibody A0024. Rat sciatic nerve lysates were used as positive control to detect big tau (white arrow). PGP 9.5 was used as a
loading control. Images are representative of five independent experiments
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albeit that under physiological conditions these isoforms
are expressed in approximately equal proportions in the
human CNS [4]. In contrast, in htau proximal colon, PCR
transcripts showed an altered relative abundance of 1 N >
2 N > 0 N (Fig. 3), and there appeared to be approximately
equal inclusion and exclusion of exon 10 (3R ≈ 4R). These
data suggest differential expression of tau isoforms in the
ENS of htau mice in comparison to those in brain.
Tau protein is expressed throughout the human and
mouse myenteric plexus
Immunohistochemistry was used to examine the localization
of tau proteins in the human and rodent ENS. Human co-
lonic myenteric plexus showed intense tau immunoreactivity
in both neuronal cell bodies and processes when pan-tau
A0024, 3R and 4R antibodies were used, which nearly
completely overlapped with beta-tubulin immunostaining
(Fig. 4a).
In order to examine the localization of tau proteins in
the ENS of htau and wild-type mice, sections of small
intestine (duodenum, jejunum, ileum) and large intestine
(proximal colon and distal colon) were dissected from
2-month-old htau, wild-type and tau knockout mice to
isolate the myenteric plexus. Tissue was immunolabelled
with an antibody against total tau (A0024). eGFP fluor-
escence was also imaged as it is inserted in tau exon 1 to
disrupt tau expression in tau knockout and htau mice
[3]. Tau proteins were found to be abundant throughout
the GI tract of htau and wild-type mice, including in the
duodenum, jejunum, ileum, proximal colon and distal
colon (Fig. 4b). There were no apparent differences in
neuronal tau localisation between these regions. Htau
proximal colon exhibited dense ganglia and axons and a
robust tau signal, whereas the axons and ganglia in htau
ileum and WT jejunum were less dense and the resulting
tau signal was comparatively less intense. Tau KO express
GFP which is observed, and show no tau immunoreactiv-
ity. Thus, tau protein is expressed in the myenteric plexus
throughout the GI tract of wild-type and htau mice.
Tau isoforms are phosphorylated in mature ENS but are
not susceptible to dephosphorylation with lambda
phosphatase
The phosphorylation of tau at multiple serine and threo-
nine sites has been described in both developing and adult
brain and is the predominant mechanism by which
tau functions are regulated [32]. This logically led us to
analyze tau phosphorylation in mature human ENS. Two
antibodies specific for tau phosphorylated at Ser202/
Thr205 (AT8) [26] and Ser396 (PHF13) [19] detected one
single band at 53–54 kDa in colon surgical specimen and
biopsies (Fig. 1b and c), thereby demonstrating that the
enteric 1N3R and 0N4R tau isoforms are phosphorylated
on serine residues under physiological conditions.
We were nevertheless struck by the fact that, in contrast
to the brain, lambda phosphatase treatment did not
appear to influence the charge/mobility of tau bands in
human colon samples when the pan-Tau antibody A0024
was used (Fig. 1a). To further investigate if tau can be
dephosphorylated in adult human ENS, colonic biopsy
Fig. 3 Detection of tau in htau and wild-type mouse brain and proximal colon. Htau (HT), wild-type (WT) and tau knock-out (KO) brain and
proximal colon cDNA was amplified using PCR with human- and mouse-tau specific primers to detect the expression of exon 2–3- (0 N),
2 + 3- (1 N), 2 + 3+ (2 N), 10- (3R) and 10+ (4R) tau isoforms. Gel images show detection of human and mouse 0 N, 1 N and 2 N tau. An insert shows a
higher intensity portion of image to illustrate tau products in proximal colon. Numbers correspond to base pairs of a DNA ladder. The expected
position of PCR product is indicated to the right of each panel. N = 3
Lionnet et al. Acta Neuropathologica Communications  (2018) 6:65 Page 8 of 17
lysates were treated with lambda phosphatase and western
blots of these samples were probed with the phospho
tau-specific antibodies AT8 (phospho-Ser202/Thr205),
PHF1 (phospho-Ser396/404) and Tau-1 (dephospho--
Ser199/202/Thr205). Antibodies against ERK were used
to check the efficiency of treatment. Although lambda
phosphatase efficiently dephosphoylated ERK, it did not
modify the phosphorylation state of tau, suggesting that
tau is relatively resistant to dephosphorylation in the
human adult ENS (Fig. 5a). To further examine tau
phosphorylation in mature ENS, we analyzed enteric
tau phosphorylation and dephosphorylation in htau
mice. Tau is phosphorylated in htau mouse ENS, as
phospho-Ser202-positive tau was detected in their
Fig. 4 Distribution and localization of tau in human, htau and wild-type mouse myenteric plexus. a Total tau antibody A0024 and the
isoform-specific antibodies against 3R and 4R-tau were used to detect tau in the myenteric plexus of a human colonic sample. An
antibody specific to betaIII-tubulin was used to specifically label neurons. Scale bar is 200 μm (b) Total tau antibody A0024 was used to detect tau in
the myenteric plexus of the duodenum, jejunum, ileum, proximal colon and distal colon of 2-month-old htau, wild-type (WT) and tau knockout (KO)
mice. Merged images show tau (red), EGFP (green) and Hoechst 33342 labelling of nucleic acids (blue). Scale bar is 100 μm. Images are representative
of three independent experiments
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colonic myenteric plexus (Fig. 5b). Samples of brain
and proximal colon from 2-month-old htau mice were
immunoblotted with the pan-Tau antibody A0024. Htau
brain showed prominent tau bands ranging from 45 to
70 kDa, in agreement with previous reports [3, 52]. Treat-
ment of these samples with lambda phosphatase to de-
phosphorylate tau showed that all six major isoforms
of tau are expressed in htau brain; these showed good
alignment with a recombinant human tau ladder (Fig. 5c).
Multiple tau immunoreactive bands ranging from ap-
proximately 25–70 kDa were detected in samples from
htau proximal colon (Fig. 5c). Two doublets of bands at
approximately 45-50 kDa and 55–60 kDa were apparent,
which likely corresponds to full-length tau with 0 or 1 N
terminal inserts, likely the 1N3R and ON4R isoforms.
Moreover, and in contrast to results with htau brain
samples, lambda phosphatase treatment did not appear to
influence the charge/mobility of tau bands in proximal
colon samples (Fig. 5c).
Tau expression levels are unaltered in the ENS in PSP
An increase of the 4R tau to 3R tau isoform ratio has
been described in some brain regions in PSP [38]. We
thus analyzed the expression levels of tau and the rela-
tive abundance of 3R and 4R isoforms in the ENS in
colonic biopsies from 5 PSP patients in comparison to
colonic samples from 10 PD patients and 9 controls
devoid of neurodegenerative disorders. Clinical features
of the study population are shown in Table 1. The ex-
pression levels of total tau as assessed by immunoblots
using the Tau-5 antibody, and the 3R/4R ratio was found
Fig. 5 Poor susceptibility of tau to dephosphorylation in mature ENS. a Sigmoid colon biopsies lysates from 2 control subjects (#183, 3 first lanes
and #208, 2 last lanes) were subjected to immunoblot analysis using TAU-5, AT8, PHF-1 and Tau-1 and antibodies. Lysates were treated
with (+ for 1 h and ++ for 3 h) or without (−) lambda phosphatase before immunoblotting. The effectiveness of dephosphorylation was
confirmed by phospho-ERK immunoblot (P-ERK immunoblot). b Antibodies against total tau (Tau antibody A0024) and tau phosphorylated
at serine 202 (CP13) (both shown in red) were used to detect tau in the myenteric plexus of the proximal colon from htau mice. eGFP expression is
shown in green, together with merged images including Hoechst 33,342 nuclear labelling (blue). Scale bars are 100 μm. N = 3. c. Brain and proximal
colon homogenates from htau mice were treated with or without lambda phosphatase (+ or -) and immunoblotted with pan-Tau antibody A0024. A
recombinant human tau ladder was included on each blot. White lines indicate rearrangement of lanes within the same blot for clarity. Data and
images are representative of three independent experiments
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not to differ between PSP samples and those from PD
and controls (Fig. 6a).
Tau phosphorylation and truncation in the ENS are
similar in PSP, PD and control subjects
Abnormal phosphorylation of tau is a characteristic fea-
ture of PSP brain [24, 49] and we therefore analyzed the
phosphorylation state of tau in colonic biopsies from
PSP patients using the AT8 and PHF-1 antibodies. There
were no apparent alterations in tau phosphorylation at
these sites in PSP samples in comparison to those from
PD and controls, or between PD and controls (Fig. 6b).
Besides abnormal phosphorylation, tau is also truncated
in the pathological deposits observed in tauopathies, and
especially in PSP [31, 51]. C-terminal tau truncation by
caspase-3 was evaluated using a Tau Asp421 antibody,
which is specific for tau cleaved at Asp421, along with an
antibody against the extreme C-terminus of tau (TP70)
[59]. Quantification of the immunoreactive bands detected
by Tau Asp421 and TP70 showed no difference in tau trun-
cation at Asp421 and the presence of an intact C-terminus,
between PD, PSP and control subjects (Fig. 6c).
Four tau isoforms are expressed and phosphorylated in
primary culture of rat ENS
Primary neuronal cultures of rat CNS neurons, which
primarily express the shortest tau isoforms 0N3R and
0N4R, have been widely used for studying tau expres-
sion, aggregation and secretion [13, 52, 56]. The brain is
not the only source from which neurons can be cultured
and there are now established protocols for the isolation
of enteric neurons from rodents and especially rats.
These have already been shown to be useful for studying
the expression of neuronal proteins involved in neurode-
generation such as alpha-synuclein [54], however the
expression pattern of tau isoforms in rat primary ENS
culture remains to be determined. As a first approach to
identify tau isoforms in cultured rat enteric neurons, we
compared the banding pattern on western blots of total
tau as evaluated with the A0024 pan-Tau antibody be-
tween primary culture of ENS and cortical neurons. In
keeping with previous observations [13, 52], this antibody
detected a tau doublet with one major band at 50 kDa and
a fainter one around 53 kDa in CNS neurons, which likely
correspond to 0N3R and 0N4R isoforms, respectively
(Fig. 7a). In ENS neurons, the observed banding pattern
was markedly different with a triplet of 50, 53 and 58 kDa
bands observed, the latter showing the most intense label-
ling (Fig. 7a). Further blotting with the 3R and 4R specific
antibodies identified 0N3R, 1N3R/0N4R and 2N3R as the
main component of the tau triplet observed in primary
culture of ENS, while 0N3R and 0N4R were the two pri-
mary tau isoforms expressed by primary culture of CNS
(Fig. 7a).
Phosphorylation of tau at multiple serine and threo-
nine sites can be modulated in primary culture of CNS
[13]. To determine whether tau phosphorylation can be
also regulated in primary culture of rat ENS, we treated
the cells with either lambda phosphatase or a combination
of serine/threonine phosphatase inhibitors. Treatment
with lambda phosphatase caused tau dephosphorylation,
as evidenced by a significant downward shift in mobility
of the tau triplet detected with either the pan-Tau A0024
or 3R antibodies (Fig. 7b). Conversely, treatment with
phosphatase inhibitors induced tau phosphorylation as
shown by upward shift in mobility of the protein on
Western blots probed with the pan-Tau A0024 antibody,
and the disappearance of all immunoreactive bands when
the Tau-1 antibody against dephosphorylated tau was used
(Fig. 7c). When the AT8 antibody was used, no signal was
observed under basal conditions, while 3 immunoreactive
bands were detected in the presence of phosphatase inhib-
itors (Fig. 7c). The PHF-1 antibody also detected three
immunoreactive bands in untreated cells. An increase in
signal intensity along with a mobility shift of all 3 bands
was observed following treatment of primary ENS cultures
with phosphatases inhibitors (Fig. 7c). Thus, the phos-
phorylation of ENS tau can be modified, at least in an in
vitro setting.
3R and 4R tau are differentially expressed in rat primary
enteric neuron cultures
Lastly, the distribution of tau in rat enteric neurons in
culture was examined by immunohistochemistry using
pan-Tau A0024, 3R and 4R-tau antibodies at 14 days in
vitro. Total tau immunoreactivity was observed in both
soma and neuronal processes and the staining patterns
produced by pan-Tau A0024, 3R-tau and beta III tubulin
antibodies were virtually superimposable (Fig. 8). The
4R-tau staining pattern was markedly different from that
observed with 3R-tau and was primarily limited to the
cell bodies (Fig. 8). These data indicate that 3R and 4R
tau species have different localization in rat primary
ENS neurons.
Discussion
Here, we have used samples of brain and gut from
humans, htau transgenic mice and rat primary cultures
to show that the isoform profile of tau differs between
the ENS and the CNS. We identified 1N3R and 0N4R as
the two main tau isoforms expressed in adult human
ENS and observed an apparent difference in the relative
abundance of different tau isoforms in htau gut and brain,
with 1 N and 2 N tau isoforms being over-represented at
mRNA levels in htau gut tissues, although 0 N and 1 N
isoforms were the predominant protein species detected.
We also found that primary culture of rat ENS express
four isoforms of tau contrasting with the predominant
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Fig. 6 Tau expression and post-translational modifications in colonic biopsies from patients progressive supranuclear palsy, Parkinson’s disease
and control subjects. a Biopsies lysates were subjected to immunoblot analysis using antibodies against total tau (TAU-5) and against 3R and 4R
isoforms. An antibody against protein gene product (PGP) 9.5 was used as a loading control. For quantification, the optical densities of
tau-immunoreactive bands were measured, normalized to the optical densities of PGP9.5 immunoreactive bands in the same samples and
expressed as percentages of controls. b Biopsies lysates were subjected to immunoblot analysis using AT8, PHF-1 and TAU-5 antibodies.
The optical densities of phospho-tau-immunoreactive bands were measured, normalized to the optical densities of TAU-5 immunoreactive bands in
the same samples, expressed as percentages of controls. c Biopsies lysates were subjected to immunoblot analysis using antibodies Tau Asp421 and
TP70. The optical densities of immunoreactive bands were measured, normalized to the optical densities of TP70 immunoreactive bands in the same
samples, expressed as percentages of controls. Data correspond to mean ± SEM for 9 control samples (C), 10 from Parkinson’s disease (PD) patients
and 5 from progressive supranuclear palsy (PSP). Immunoblot (IB)
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expression of the single fetal tau 0N3R isoform in rat
primary cortical neurons. The ENS and the CNS both
contain integrated nervous networks and the similarities
between them, including between neurons and glia at a
morphological level, have led to the ENS being described
as the ‘brain in the gut’ or the ‘second brain’ [22]. Our
current and previous results suggest that this anatomical
resemblance does not extend to the molecular level as the
ENS expresses only a limited number of isoforms of neur-
onal and glial markers as compared to the brain [10],
although the functional consequences of these differences
still remain to be determined.
Tau was found to be expressed in both the myenteric
and submucosal plexus of human colon and throughout
the ENS of wild-type mice and in the htau mouse model.
In both the human and rodent ENS, tau protein had a
mainly axonal and somatic distribution, which might be
expected since in physiological conditions, tau is described
as being a predominantly axonal protein [32]. The pres-
ence of nuclear tau has been documented in a wide variety
Fig. 7 Tau isoform profile and phosphorylation state in rat primary culture of ENS. a Lysates of rat primary ENS and CNS cultures were subjected
to immunoblot analysis using the pan-Tau antibody A0024 and the isoform specific antibodies 3R and 4R. b Primary culture lysates were treated
with (+) or without (−) lambda phosphatase before immunoblot analysis with the pan-Tau antibody A0024 and the isoform specific antibody
against 3R-tau. PGP9.5 was used as a loading control. c Primary culture of rat ENS were treated (+) or not (−) with a cocktail of 3 phosphatase
inhibitors including 1 μM okadaic acid, 1 μM ciclosporine A and 6.75 μM sanguinarine (Ppase inhibitors) for 1 h. Fifteen μg of cell lysates were
subjected to immunoblot analysis using Tau-1, AT8 and PHF-1 antibodies. IB is for immunoblot. The results shown in (a), (b) and (c) are
representative of 2, 4 and 3 independent experiments, respectively
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of cell and animal systems, including human and rodent
brains and neuronal cell lines (reviewed in [32]). So far,
the transcript encoding nuclear tau has not been formally
identified but findings obtained in mouse brain suggest
that the 1N4R isoform is preferentially localised in the
nucleus [46]. Although our immunofluorescence experi-
ments performed in mature human and mouse ENS, as
well as in primary culture of rat ENS, clearly showed that
tau was mainly axonal and somatic, we cannot rule out
that a small proportion of enteric tau could also be nuclear.
Further experiments including high resolution imaging
and biochemical subcellular fractionation will be needed to
answer this question.
A panel of well-characterised phospho-specific tau anti-
bodies were used to show that tau is phosphorylated in
the ENS of healthy subjects at Ser202/Thr205 and Ser396/
Ser404. Tau is known to be phosphorylated at these sites
under physiological conditions, with elevated phosphor-
ylation at these epitopes chacteristic of pathological
conditions in the CNS (reviewed in [53]). There is mount-
ing evidence to suggest that tau phosphorylation plays a
key role in neuronal physiology. The function of tau is
strongly affected by its phosphorylation status, influencing
its ability to interact with signaling proteins and kinases
[57], its association with microtubules and membranes
and its ability to regulate axonal transport [58]. Phosphor-
ylation of Ser202/Thr205 and Ser396/Ser404 is commonly
found in primary cortical neurons under basal conditions
[2] as well as in snap-frozen brain biopsies from subject
devoid of neurodegenerative conditions [47], suggesting
that these sites are involved in the normal physiology of
the CNS. This is further reinforced by the recent
observation showing the presence of endogenous tau phos-
phorylated at these sites at postsynaptic sites in hippocam-
pal neurons where tau interacts with the PSD95-NMDA
receptor complex to regulate synaptic activity [48]. These
results obtained in the CNS could be extended to the ENS
where neuronal plasticity has also been described following
modulation of neuronal activity [9, 37].
Soluble tau from adult human brain consist of a het-
erogeneous mixture of tau isoforms in multiple states of
phosphorylation [25, 28]. Because normal electrophor-
esis techniques do not separate the individual tau iso-
forms, correct identification of the isoform composition
of soluble tau requires an efficient dephosphorylation
reaction with lambda phosphatase before immunoblot-
ting [35]. Dephosphorylation of tau from normal adult
human brain classically produces a downwards shift
enabling a more precise separation and identification of
the six tau isoforms [25, 35]. We therefore used the
same approach in mature human ENS and the gut of
htau mice. In sharp contrast to results with human and
htau brain samples, lambda phosphatase treatment did
not change the charge/mobility of tau bands in colon
samples, suggesting that gut tau may have not been effi-
ciently dephosphorylated. Since western blot and im-
munohistochemical findings showed that tau in gut is
in fact phosphorylated, at least at Ser202, Thr205 and
Ser396/ Ser404 this raises the possibility that ENS tau
is modified in such a way that it is not susceptible to
dephosphorylation. This relative resistance to dephos-
phorylation, which might be due to conformational
changes occurring in case of phosphorylation at some
specific sites [18], is specific to adult ENS tau as lambda
Fig. 8 Distribution and localization of tau in primary culture of rat ENS. After 14 days in culture, primary culture of rat ENS were immunostained
with the pan-Tau antibody A0024 and the isoforms specific antibodies against 3R and 4R-tau. Scale bar is 100 μM
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phosphatase efficiently dephosphorylated tau in rat pri-
mary ENS cultures prepared from fetal rats.
In 1978 the first study on cultured myenteric neurons
was published [40] and since then there has been a
growing interest in this method with several different
culture preparations being developed. Using primary cul-
tures of rat ENS [9, 11], we have shown that fetal rat
enteric neurons express four isoforms of tau, including
the three 3R isoforms. This again stands in sharp contrast
to the CNS as rat primary cortical neurons primarily ex-
press the 0N3R isoform (our study and [13]). We also show
that tau isoforms present in primary ENS culture are phos-
phorylated under basal conditions and their levels of phos-
phorylation can be down or upregulated. This suggests
that cultured ENS might be helpful to study the regulation
of tau expression, phosphorylation and secretion not only
in physiological conditions but also in the context of en-
teric neuropathies [55].
We did not observe any pathological tau changes in
the ENS of PSP patients. This stands in sharp contrast
with the fact that PSP is considered a prototypical tauopa-
thy of the CNS characterized by tau hyperphosphorylation
and truncation [31, 67] and an imbalance in 4R/3R ratio
[38]. We have recently proposed that the ENS may be a
mirror on to the PD pathology of the CNS since it recapit-
ulates several of the neuronal and glial changes observed
in the brain [10, 15, 45]. Our results suggest that, unlike
PD, the pathological process in PSP is limited to the CNS
and does not involve the ENS. This is supported by the
paucity of studies reporting that the peripheral nervous
systems are affected in PSP (reviewed in [64]) and by our
observation of a lack of glial reaction in the gut in PSP
patients [10]. One obvious limitation of this work is that
our analysis of PSP samples was restricted to the analysis
of the submucosal plexus. We can therefore not rule out
that the absence of overt pathological changes in tau in
colonic samples from our PSP patients may be due to this
limited regional analysis and perhaps different findings
would have been obtained had we examined the myenteric
plexus. The refinement of new endoscopic procedures,
such as full thickness biopsies [50], which provide access
to both myenteric and submucosal plexi, may help to
answer these critical questions. A second limitation in our
study is the lack of neuropathological confirmation of PD
and PSP, as the clinical diagnosis of both disorders may
have a relatively poor accuracy [1, 42], especially for PD
patients for whom signs and symptoms have been present
for less than 5 years [1]. In addition, we can not rule out
that some of our control subjects may have asymptomatic
tauopathy [12].
Conclusions
We have characterised tau in the human and rodent
ENS under physiological conditions and tauopathies. We
show differences in tau isoform expression at mRNA
and protein level, and in the susceptibility of tau to be
dephosphorylated in the CNS and ENS. The data we
have acquired on tau in the ENS strongly supports add-
itional future studies aimed at expanding our knowledge
of peripheral pathology in neurodegenrative disorders of
the CNS and in enteric neuropathies [14].
Additional file
Additional file 1: Figure S1. Validation of the Cosmo-bio 4R antibody.
(PDF 220 kb)
Abbreviations
AD: Alzheimer’s disease; BSA: Bovine serum albumen; CNS: Central nervous
system; ENS: Enteric nervous system; ERK: Extracellular signal-regulated ki-
nases; GI: Gastrointestinal; KO: Knockout; MP: Myenteric plexus;
PCR: Polymerase chain reaction; PD: Parkinson’s disease; PSP: Progressive
supranuclear palsy; Ser: Serine; SMP: Submucosal plexus; TBS: Tris-buffered
saline; Thr: Threonine
Acknowledgements
We are grateful to Professor Peter Davies (Feinstein Institute for Medical
Research, NY, USA) for his generous gift of tau antibodies.
Funding
This work was supported by BBSRC/AstraZeneca (BB/L502601/1 to WN), the
National Centre for the Replacement, Refinement and Reduction of Animals
in Research (NC3Rs, NC/K500343/1 to WN), CECAP, FFGP and PSP France
(to AP and PD).
Availability of data and materials
The datasets used and/or analysed during the current study available from
the corresponding author on reasonable request.
Authors’ contributions
AL, MAW, AGC, AP, SP, MT and JG performed the experiments and analyzed
the data. ED and MRD managed the biobanking and dissected the colonic
samples. ED and EC performed the endoscopy. MAW, PD, MN, DPH, MSP and
WN designed the research and MAW, WN and PD wrote the manuscript. All
authors read and approved the final manuscript.
Ethics approval and consent to participate
All housing and experimental procedures were carried out in compliance
with the local ethical review panel of King’s College London under a UK
Home Office project license held in accordance with the Animals (Scientific
Procedures) Act 1986 and the European Directive 2010/63/EU. Regarding
sigmoid biopsies sampling, the study protocol was approved by the local
Committee on Ethics and Human Research (Comité de Protection des
Personnes Ouest VI), and registered on ClinicalTrials.gov (EnteroLark and
ColoBioParker, identifier NCT01618383 and NCT01353183, respectively).
Written informed consent was obtained from each patient and from each
normal volunteer.
Consent for publication
Not applicable.
Competing interests
Michael S. Perkinton is an employee of MedImmune.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Inserm, U1235, 1 rue Gaston Veil, F-44035 Nantes, France. 2Department of
Neurology, CHU Nantes, F-44093 Nantes, France. 3University Nantes, F-44000
Lionnet et al. Acta Neuropathologica Communications  (2018) 6:65 Page 15 of 17
Nantes, France. 4King’s College London, Institute of Psychiatry, Psychology
and Neuroscience, Department of Basic and Clinical Neuroscience, Maurice
Wohl Clinical Neuroscience Institute, Rm 1.23, 5 Cutcombe Road,
Camberwell, London SE5 9RX, UK. 5Neuroscience, IMED Biotech Unit,
AstraZeneca, Cambridge CB21 6GH, UK.
Received: 14 June 2018 Accepted: 6 July 2018
References
1. Adler CH, Beach TG, Hentz JG, Shill HA, Caviness JN, Driver-Dunckley E et al
(2014) Low clinical diagnostic accuracy of early vs advanced Parkinson
disease: clinicopathologic study. Neurology 83:406–412. https://doi.org/10.
1212/WNL.0000000000000641
2. Anderton BH, Brion JP, Couck AM, Davis DR, Gallo JM, Hanger DP et al
(1995) Modulation of PHF-like tau phosphorylation in cultured neurones
and transfected cells. Neurobiol Aging 16:389–397 discussion 398-402
3. Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde Y-A et al (2003)
Hyperphosphorylation and aggregation of tau in mice expressing normal
human tau isoforms. J Neurochem 86:582–590
4. Andreadis A (2005) Tau gene alternative splicing: expression patterns,
regulation and modulation of function in normal brain and
neurodegenerative diseases. Biochim Biophys Acta 1739:91–103. https://doi.
org/10.1016/j.bbadis.2004.08.010
5. Barrenschee M, Zorenkov D, Böttner M, Lange C, Cossais F, Scharf AB et al
(2017) Distinct pattern of enteric phospho-alpha-synuclein aggregates and
gene expression profiles in patients with Parkinson’s disease. Acta
Neuropathol Commun 5:1. https://doi.org/10.1186/s40478-016-0408-2
6. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL et al (2010) Multi-
organ distribution of phosphorylated alpha-synuclein histopathology in
subjects with Lewy body disorders. Acta Neuropathol 119:689–702. https://
doi.org/10.1007/s00401-010-0664-3
7. Bussière T, Hof PR, Mailliot C, Brown CD, Caillet-Boudin ML, Perl DP et al
(1999) Phosphorylated serine422 on tau proteins is a pathological epitope
found in several diseases with neurofibrillary degeneration. Acta
Neuropathol 97:221–230
8. Chambonnière ML, Mosnier-Damet M, Mosnier JF (2001) Expression of
microtubule-associated protein tau by gastrointestinal stromal tumors. Hum
Pathol 32:1166–1173
9. Chevalier J, Derkinderen P, Gomes P, Thinard R, Naveilhan P, Vanden Berghe
P, Neunlist M (2008) Activity-dependent regulation of tyrosine hydroxylase
expression in the enteric nervous system. J Physiol Lond 586:1963–1975.
https://doi.org/10.1113/jphysiol.2007.149815
10. Clairembault T, Kamphuis W, Leclair-Visonneau L, Rolli-Derkinderen M, Coron E,
Neunlist M et al (2014) Enteric GFAP expression and phosphorylation in
Parkinson’s disease. J Neurochem 130:805–815. https://doi.org/10.1111/jnc.12742
11. Coquenlorge S, Duchalais E, Chevalier J, Cossais F, Rolli-Derkinderen M,
Neunlist M (2014) Modulation of lipopolysaccharide-induced neuronal
response by activation of the enteric nervous system. J Neuroinflammation
11:202. https://doi.org/10.1186/s12974-014-0202-7
12. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I
et al (2014) Primary age-related tauopathy (PART): a common pathology
associated with human aging. Acta Neuropathol 128:755–766. https://doi.
org/10.1007/s00401-014-1349-0
13. Davis DR, Brion JP, Couck AM, Gallo JM, Hanger DP, Ladhani K et al (1995)
The phosphorylation state of the microtubule-associated protein tau as
affected by glutamate, colchicine and beta-amyloid in primary rat cortical
neuronal cultures. Biochem J 309(Pt 3):941–949
14. De Giorgio R, Bianco F, Latorre R, Caio G, Clavenzani P, Bonora E (2016)
Enteric neuropathies: yesterday, today and tomorrow. Adv Exp Med Biol
891:123–133. https://doi.org/10.1007/978-3-319-27592-5_12
15. Devos D, Lebouvier T, Lardeux B, Biraud M, Rouaud T, Pouclet H et al (2013)
Colonic inflammation in Parkinson’s disease. Neurobiol Dis 50:42–48. https://
doi.org/10.1016/j.nbd.2012.09.007
16. Duff K, Knight H, Refolo LM, Sanders S, Yu X, Picciano M et al (2000)
Characterization of pathology in transgenic mice over-expressing human
genomic and cDNA tau transgenes. Neurobiol Dis 7:87–98. https://doi.org/
10.1006/nbdi.1999.0279
17. Dugger BN, Whiteside CM, Maarouf CL, Walker DG, Beach TG, Sue LI et al
(2016) The presence of select tau species in human peripheral tissues and
their relation to Alzheimer’s disease. J Alzheimers Dis 51:345–356. https://
doi.org/10.3233/JAD-150859
18. Dupont-Wallois L, Sautière PE, Cocquerelle C, Bailleul B, Delacourte A,
Caillet-Boudin ML (1995) Shift from fetal-type to Alzheimer-type
phosphorylated tau proteins in SKNSH-SY 5Y cells treated with okadaic acid.
FEBS Lett 357:197–201
19. Ercan E, Eid S, Weber C, Kowalski A, Bichmann M, Behrendt A et al
(2017) A validated antibody panel for the characterization of tau post-
translational modifications. Mol Neurodegener 12:87. https://doi.org/10.
1186/s13024-017-0229-1
20. Fischer D, Mukrasch MD, Biernat J, Bibow S, Blackledge M, Griesinger C et al
(2009) Conformational changes specific for pseudophosphorylation at serine
262 selectively impair binding of tau to microtubules. Biochemistry 48:
10047–10055. https://doi.org/10.1021/bi901090m
21. Gelpi E, Navarro-Otano J, Tolosa E, Gaig C, Compta Y, Rey MJ et al (2014)
Multiple organ involvement by alpha-synuclein pathology in Lewy body
disorders. Mov Disord 29:1010–1018. https://doi.org/10.1002/mds.25776
22. Gershon MD (1999) The enteric nervous system: a second brain. Hosp Pract
(1995) 34:31–32 35–38, 41–42 passim
23. Giancola F, Torresan F, Repossi R, Bianco F, Latorre R, Ioannou A et al (2017)
Downregulation of neuronal vasoactive intestinal polypeptide in Parkinson’s
disease and chronic constipation. Neurogastroenterol Motil 29. https://doi.
org/10.1111/nmo.12995
24. Gibb GM, de Silva R, Revesz T, Lees AJ, Anderton BH, Hanger DP (2004)
Differential involvement and heterogeneous phosphorylation of tau isoforms
in progressive supranuclear palsy. Brain Res Mol Brain Res 121:95–101. https://
doi.org/10.1016/j.molbrainres.2003.11.007
25. Goedert M, Jakes R (1990) Expression of separate isoforms of human tau
protein: correlation with the tau pattern in brain and effects on tubulin
polymerization. EMBO J 9:4225–4230
26. Goedert M, Jakes R, Vanmechelen E (1995) Monoclonal antibody AT8
recognises tau protein phosphorylated at both serine 202 and threonine
205. Neurosci Lett 189:167–169
27. Goedert M, Spillantini MG, Crowther RA (1992) Cloning of a big tau
microtubule-associated protein characteristic of the peripheral nervous
system. Proc Natl Acad Sci U S A 89:1983–1987
28. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA (1989) Multiple
isoforms of human microtubule-associated protein tau: sequences and
localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 3:519–526
29. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986)
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in
Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83:4913–4917
30. Gu Y, Oyama F, Ihara Y (1996) Tau is widely expressed in rat tissues.
J Neurochem 67:1235–1244
31. Guillozet-Bongaarts AL, Glajch KE, Libson EG, Cahill ME, Bigio E, Berry RW,
Binder LI (2007) Phosphorylation and cleavage of tau in non-AD
tauopathies. Acta Neuropathol 113:513–520. https://doi.org/10.1007/s00401-
007-0209-6
32. Guo T, Noble W, Hanger DP (2017) Roles of tau protein in health and disease.
Acta Neuropathol 133:665–704. https://doi.org/10.1007/s00401-017-1707-9
33. Haïk S, Faucheux BA, Sazdovitch V, Privat N, Kemeny J-L, Perret-Liaudet A,
Hauw J-J (2003) The sympathetic nervous system is involved in variant
Creutzfeldt-Jakob disease. Nat Med 9:1121–1123. https://doi.org/10.1038/
nm922
34. Hanger DP, Byers HL, Wray S, Leung K-Y, Saxton MJ, Seereeram A, Reynolds
CH et al (2007) Novel phosphorylation sites in tau from Alzheimer brain
support a role for casein kinase 1 in disease pathogenesis. J Biol Chem 282:
23645–23654. https://doi.org/10.1074/jbc.M703269200
35. Hanger DP, Gibb GM, de Silva R, Boutajangout A, Brion J-P, Revesz T et al
(2002) The complex relationship between soluble and insoluble tau in
tauopathies revealed by efficient dephosphorylation and specific antibodies.
FEBS Lett 531:538–542
36. Heumüller-Klug S, Sticht C, Kaiser K, Wink E, Hagl C, Wessel L, Schäfer K-H
(2015) Degradation of intestinal mRNA: a matter of treatment. World J
Gastroenterol 21:3499–3508. https://doi.org/10.3748/wjg.v21.i12.3499
37. Hons IM, Storr MA, Mackie K, Lutz B, Pittman QJ, Mawe GM, Sharkey KA
(2012) Plasticity of mouse enteric synapses mediated through
endocannabinoid and purinergic signaling. Neurogastroenterol Motil 24:
e113–e124. https://doi.org/10.1111/j.1365-2982.2011.01860.x
38. Ingelsson M, Ramasamy K, Russ C, Freeman SH, Orne J, Raju S et al (2007)
Increase in the relative expression of tau with four microtubule binding
Lionnet et al. Acta Neuropathologica Communications  (2018) 6:65 Page 16 of 17
repeat regions in frontotemporal lobar degeneration and progressive
supranuclear palsy brains. Acta Neuropathol 114:471–479. https://doi.org/10.
1007/s00401-007-0280-z
39. Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW (2003) Colocalization of
tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol
62:389–397
40. Jessen KR, McConnell JD, Purves RD, Burnstock G, Chamley-Campbell J
(1978) Tissue culture of mammalian enteric neurons. Brain Res 152:573–579
41. Joiner S, Linehan JM, Brandner S, Wadsworth JDF, Collinge J (2005) High
levels of disease related prion protein in the ileum in variant Creutzfeldt-
Jakob disease. Gut 54:1506–1508. https://doi.org/10.1136/gut.2005.072447
42. Joutsa J, Gardberg M, Röyttä M, Kaasinen V (2014) Diagnostic accuracy of
parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord
20:840–844. https://doi.org/10.1016/j.parkreldis.2014.04.019
43. Kovacs GG (2017) Tauopathies. Handb Clin Neurol 145:355–368. https://doi.
org/10.1016/B978-0-12-802395-2.00025-0
44. Lebouvier T, Coron E, Chaumette T, Paillusson S, Bruley d, Varannes S,
Neunlist M, Derkinderen P (2010) Routine colonic biopsies as a new tool to
study the enteric nervous system in living patients. Neurogastroenterol
Motil 22:e11–e14. https://doi.org/10.1111/j.1365-2982.2009.01368.x
45. Lebouvier T, Neunlist M, Bruley d, Varannes S, Coron E, Drouard A, N’Guyen
J-M et al (2010) Colonic biopsies to assess the neuropathology of
Parkinson’s disease and its relationship with symptoms. PLoS One 5:e12728.
https://doi.org/10.1371/journal.pone.0012728
46. Liu C, Götz J (2013) Profiling murine tau with 0N, 1N and 2N isoform-
specific antibodies in brain and peripheral organs reveals distinct subcellular
localization, with the 1N isoform being enriched in the nucleus. PLoS One
8:e84849. https://doi.org/10.1371/journal.pone.0084849
47. Matsuo ES, Shin RW, Billingsley ML, Van deVoorde A, O’Connor M,
Trojanowski JQ, Lee VM (1994) Biopsy-derived adult human brain tau is
phosphorylated at many of the same sites as Alzheimer’s disease paired
helical filament tau. Neuron 13:989–1002
48. Mondragón-Rodríguez S, Trillaud-Doppia E, Dudilot A, Bourgeois C, Lauzon
M, Leclerc N, Boehm J (2012) Interaction of endogenous tau protein with
synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent
tau phosphorylation. J Biol Chem 287:32040–32053. https://doi.org/10.1074/
jbc.M112.401240
49. Morris HR, Gibb G, Katzenschlager R, Wood NW, Hanger DP, Strand C et al
(2002) Pathological, clinical and genetic heterogeneity in progressive
supranuclear palsy. Brain 125:969–975. https://doi.org/10.1093/brain/awf109
50. Neunlist M, Coquenlorge S, Aubert P, Duchalais-Dassonneville E, des
Varannes SB, Meurette G, Coron E (2011) Colonic endoscopic full-thickness
biopsies: from the neuropathological analysis of the myenteric plexus to the
functional study of neuromuscular transmission. Gastrointest Endosc 73:
1029–1034. https://doi.org/10.1016/j.gie.2011.01.041
51. Newman J, Rissman RA, Sarsoza F, Kim RC, Dick M, Bennett DA et al (2005)
Caspase-cleaved tau accumulation in neurodegenerative diseases associated
with tau and alpha-synuclein pathology. Acta Neuropathol 110:135–144.
https://doi.org/10.1007/s00401-005-1027-3
52. Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderton BH
(2009) Minocycline reduces the development of abnormal tau species in
models of Alzheimer’s disease. FASEB J 23:739–750. https://doi.org/10.1096/
fj.08-113795
53. Noble W, Hanger DP, Miller CCJ, Lovestone S (2013) The importance of tau
phosphorylation for neurodegenerative diseases. Front Neurol 4:83. https://
doi.org/10.3389/fneur.2013.00083
54. Paillusson S, Tasselli M, Lebouvier T, Mahé MM, Chevalier J, Biraud M et al
(2010) α-Synuclein expression is induced by depolarization and cyclic AMP
in enteric neurons. J Neurochem 115:694–706. https://doi.org/10.1111/j.
1471-4159.2010.06962.x
55. Phillips RJ, Walter GC, Ringer BE, Higgs KM, Powley TL (2009) Alpha-
synuclein immunopositive aggregates in the myenteric plexus of the aging
Fischer 344 rat. Exp Neurol 220:109–119. https://doi.org/10.1016/j.expneurol.
2009.07.025
56. Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP (2012)
Dynamic association of tau with neuronal membranes is regulated by
phosphorylation. Neurobiol Aging 33:431.e27–431.e38. https://doi.org/10.
1016/j.neurobiolaging.2011.01.005
57. Reynolds CH, Garwood CJ, Wray S, Price C, Kellie S, Perera T et al (2008)
Phosphorylation regulates tau interactions with Src homology 3 domains of
phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src
family kinases. J Biol Chem 283:18177–18186. https://doi.org/10.1074/jbc.
M709715200
58. Rodríguez-Martín T, Cuchillo-Ibáñez I, Noble W, Nyenya F, Anderton BH,
Hanger DP (2013) Tau phosphorylation affects its axonal transport and
degradation. Neurobiol Aging 34:2146–2157. https://doi.org/10.1016/j.
neurobiolaging.2013.03.015
59. Takuma H, Arawaka S, Mori H (2003) Isoforms changes of tau protein during
development in various species. Brain Res Dev Brain Res 142:121–127
60. Taleghany N, Oblinger MM (1992) Regional distribution and biochemical
characteristics of high molecular weight tau in the nervous system.
J Neurosci Res 33:257–265. https://doi.org/10.1002/jnr.490330209
61. Tam PK (1990) An immunohistological study of the human enteric nervous
system with microtubule-associated proteins. Gastroenterology 99:1841–1844
62. Tasselli M, Chaumette T, Paillusson S, Monnet Y, Lafoux A, Huchet-Cadiou C
et al (2013) Effects of oral administration of rotenone on gastrointestinal
functions in mice. Neurogastroenterol Motil 25:e183–e193. https://doi.org/
10.1111/nmo.12070
63. Usardi A, Pooler AM, Seereeram A, Reynolds CH, Derkinderen P, Anderton B
et al (2011) Tyrosine phosphorylation of tau regulates its interactions with
Fyn SH2 domains, but not SH3 domains, altering the cellular localization of
tau. FEBS J 278:2927–2937. https://doi.org/10.1111/j.1742-4658.2011.08218.x
64. Wakabayashi K, Mori F, Tanji K, Orimo S, Takahashi H (2010) Involvement of the
peripheral nervous system in synucleinopathies, tauopathies and other
neurodegenerative proteinopathies of the brain. Acta Neuropathol 120:1–12.
https://doi.org/10.1007/s00401-010-0706-x
65. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F (1988) Parkinson’s
disease: the presence of Lewy bodies in Auerbach’s and Meissner’s plexuses.
Acta Neuropathol 76:217–221
66. Wills J, Credle J, Haggerty T, Lee J-H, Oaks AW, Sidhu A (2011) Tauopathic
changes in the striatum of A53T α-synuclein mutant mouse model of
Parkinson’s disease. PLoS One 6:e17953. https://doi.org/10.1371/journal.
pone.0017953
67. Wray S, Saxton M, Anderton BH, Hanger DP (2008) Direct analysis of tau from
PSP brain identifies new phosphorylation sites and a major fragment of N-
terminally cleaved tau containing four microtubule-binding repeats.
J Neurochem 105:2343–2352. https://doi.org/10.1111/j.1471-4159.2008.05321.x
Lionnet et al. Acta Neuropathologica Communications  (2018) 6:65 Page 17 of 17
